OpenLB
Open Library of Bioscience
Advanced Search
Clinical and experimental gastroenterology
2014;7 359-67.

Management of inflammatory bowel disease in poor responders to infliximab.

Iván Guerra, Fernando Bermejo
Author Information
  1. Iván Guerra: Gastroenterology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
  2. Fernando Bermejo: Gastroenterology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
PMID: 25258548 DOI: 10.2147/CEG.S45297

Abstract

Infliximab (IFX) is an effective treatment for inducing and maintaining response in Crohn's disease and ulcerative colitis patients. Some patients present lack of response or loss of response to IFX during maintenance therapy. Empirical management with combination therapy with an immunomodulator, IFX dose escalation, or switching IFX for another antitumor necrosis factor-α drug, mainly adalimumab, is common in clinical practice. Selecting the best choice with the help of serum drug concentrations and trough IFX antibody concentrations could be a very interesting approach. In addition to surgery, a broad spectrum of new drugs has been tested and could expand treatment options in the near future.

Keywords

Crohn’s disease anti-TNF inflammatory bowel disease infliximab treatment ulcerative colitis

References

  1. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6 [PMID: 17324398]
  2. Aliment Pharmacol Ther. 2013 Jun;37(12):1172-83 [PMID: 23650912]
  3. Inflamm Bowel Dis. 2014 Jan;20(1):1-6 [PMID: 24280879]
  4. Gastroenterology. 2009 Nov;137(5):1628-40 [PMID: 19664627]
  5. Aliment Pharmacol Ther. 2011 Feb;33(3):340-8 [PMID: 21133961]
  6. Aliment Pharmacol Ther. 2009 Mar 1;29(5):527-34 [PMID: 19183339]
  7. J Gastrointestin Liver Dis. 2013 Sep;22(3):269-76 [PMID: 24078983]
  8. N Engl J Med. 2010 Apr 15;362(15):1383-95 [PMID: 20393175]
  9. Aliment Pharmacol Ther. 2011 Aug;34(4):462-9 [PMID: 21671970]
  10. Clin Gastroenterol Hepatol. 2012 Jan;10(1):46-51 [PMID: 21963958]
  11. Inflamm Bowel Dis. 2012 Jan;18(1):1-9 [PMID: 21351211]
  12. Gut. 2009 Dec;58(12):1612-9 [PMID: 19700435]
  13. Gut. 2010 Jan;59(1):49-54 [PMID: 19651627]
  14. Gastroenterology. 2014 Feb;146(2):392-400.e3 [PMID: 24512909]
  15. J Crohns Colitis. 2012 Mar;6(2):248-58 [PMID: 22325181]
  16. Aliment Pharmacol Ther. 2014 Apr;39(7):660-71 [PMID: 24506179]
  17. Gastroenterology. 2007 Jan;132(1):52-65 [PMID: 17241859]
  18. J Crohns Colitis. 2012 Feb;6(1):62-7 [PMID: 22261529]
  19. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1474-81.e2; quiz e91 [PMID: 24486408]
  20. Aliment Pharmacol Ther. 2009 Nov 15;30(10):977-86 [PMID: 19681810]
  21. Inflamm Bowel Dis. 2010 Dec;16(12):2090-8 [PMID: 20848504]
  22. Inflamm Bowel Dis. 2013 Sep;19(10):2111-7 [PMID: 23883959]
  23. Clin Gastroenterol Hepatol. 2006 Oct;4(10):1248-54 [PMID: 16931170]
  24. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1509-20 [PMID: 17931345]
  25. N Engl J Med. 2013 Aug 22;369(8):699-710 [PMID: 23964932]
  26. Gastroenterology. 2014 Jan;146(1):96-109.e1 [PMID: 23770005]
  27. Aliment Pharmacol Ther. 2011 Jul;34(1):1-10 [PMID: 21539588]
  28. J Crohns Colitis. 2012 Mar;6(2):143-53 [PMID: 22325168]
  29. N Engl J Med. 2006 Mar 2;354(9):924-33 [PMID: 16510746]
  30. Am J Gastroenterol. 2004 Oct;99(10):1984-9 [PMID: 15447761]
  31. Inflamm Bowel Dis. 2007 Sep;13(9):1093-9 [PMID: 17480021]
  32. Am J Gastroenterol. 2005 Jan;100(1):75-9 [PMID: 15654784]
  33. J Crohns Colitis. 2012 Dec;6(10):991-1030 [PMID: 23040451]
  34. Gut. 2009 Apr;58(4):492-500 [PMID: 18832518]
  35. Curr Opin Gastroenterol. 2013 Jul;29(4):391-6 [PMID: 23703367]
  36. Aliment Pharmacol Ther. 2012 Mar;35(5):562-7 [PMID: 22239070]
  37. Am J Gastroenterol. 2013 Jun;108(6):962-71 [PMID: 23419382]
  38. N Engl J Med. 2013 Aug 22;369(8):711-21 [PMID: 23964933]
  39. Am J Gastroenterol. 2008 Apr;103(4):944-8 [PMID: 18028512]
  40. Gastroenterology. 2014 Mar;146(3):681-688.e1 [PMID: 24269926]
  41. Gastroenterology. 2008 Jun;134(7):1861-8 [PMID: 18440315]
  42. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2 [PMID: 20451663]
  43. Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459 [PMID: 23235598]
  44. J Crohns Colitis. 2010 Feb;4(1):28-62 [PMID: 21122489]
  45. Eur J Gastroenterol Hepatol. 2009 Sep;21(9):1042-8 [PMID: 20139856]
  46. Int J Clin Pharmacol Ther. 2010 May;48(5):297-308 [PMID: 20420786]
  47. Aliment Pharmacol Ther. 2010 Nov;32(10):1228-39 [PMID: 20955442]
  48. J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7 [PMID: 17255842]
  49. Aliment Pharmacol Ther. 2014 Mar;39(6):579-94 [PMID: 24479980]
  50. Lancet. 2002 May 4;359(9317):1541-9 [PMID: 12047962]
  51. Inflamm Bowel Dis. 2009 Jun;15(6):829-36 [PMID: 19130617]
  52. Ann Intern Med. 2007 Jun 19;146(12):829-38 [PMID: 17470824]
  53. Am J Gastroenterol. 2013 Jan;108(1):40-7; quiz 48 [PMID: 23147525]
  54. Am J Gastroenterol. 2009 Mar;104(3):760-7 [PMID: 19174781]
  55. Dig Liver Dis. 2014 Feb;46(2):135-9 [PMID: 24246151]
  56. Gastroenterology. 2007 May;132(5):1672-83 [PMID: 17484865]
  57. Gastroenterology. 2013 Dec;145(6):1459-63 [PMID: 24267474]
  58. Can J Gastroenterol. 2011 Aug;25(8):419-25 [PMID: 21912766]
  59. N Engl J Med. 2012 Oct 18;367(16):1519-28 [PMID: 23075178]
  60. N Engl J Med. 2005 Dec 8;353(23):2462-76 [PMID: 16339095]
  61. Gastroenterology. 2003 Apr;124(4):917-24 [PMID: 12671888]
  62. Inflamm Bowel Dis. 2012 Nov;18(11):2011-7 [PMID: 22223566]
  63. Gut. 2014 Nov;63(11):1721-7 [PMID: 24474383]
  64. Curr Drug Metab. 2011 Jul;12(6):594-8 [PMID: 21495977]
  65. Aliment Pharmacol Ther. 2007 Jan 1;25(1):19-37 [PMID: 17229218]
  66. J Crohns Colitis. 2011 Dec;5(6):543-9 [PMID: 22115372]
  67. N Engl J Med. 2004 Feb 26;350(9):876-85 [PMID: 14985485]
  68. Aliment Pharmacol Ther. 2011 Feb;33(3):349-57 [PMID: 21118397]
  69. Gut. 2014 Jun;63(6):919-27 [PMID: 23878167]
  70. Clin Pharmacokinet. 2010 Oct;49(10):633-59 [PMID: 20818831]
  71. J Crohns Colitis. 2013 Feb;7(1):34-43 [PMID: 22480772]
Journal Article Review
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0IFXdiseasetreatmentresponseulcerativecolitispatientstherapydrugconcentrationsinflammatorybowelinfliximabInfliximabeffectiveinducingmaintainingCrohn'spresentlacklossmaintenanceEmpiricalmanagementcombinationimmunomodulatordoseescalationswitchinganotherantitumornecrosisfactor-αmainlyadalimumabcommonclinicalpracticeSelectingbestchoicehelpserumtroughantibodyinterestingapproachadditionsurgerybroadspectrumnewdrugstestedexpandoptionsnearfutureManagementpoorrespondersCrohn’santi-TNF

Similar Articles

Cited By